Poseida Therapeutics’ (PSTX) “Neutral” Rating Reiterated at BTIG Research

Poseida Therapeutics (NASDAQ:PSTX)‘s stock had its “neutral” rating reissued by equities researchers at BTIG Research in a note issued to investors on Tuesday,Benzinga reports.

PSTX has been the topic of several other research reports. HC Wainwright reaffirmed a “neutral” rating and set a $9.00 price target (down previously from $20.00) on shares of Poseida Therapeutics in a research report on Tuesday. William Blair reiterated a “market perform” rating on shares of Poseida Therapeutics in a research note on Tuesday. Four research analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $9.50.

Poseida Therapeutics Stock Performance

Shares of PSTX stock opened at $9.33 on Tuesday. The company has a debt-to-equity ratio of 0.68, a quick ratio of 3.20 and a current ratio of 3.20. Poseida Therapeutics has a one year low of $1.87 and a one year high of $9.42. The company’s 50-day simple moving average is $3.02 and its 200-day simple moving average is $3.01. The stock has a market capitalization of $909.35 million, a price-to-earnings ratio of -14.81 and a beta of 0.54.

Insider Buying and Selling

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 26th. The shares were sold at an average price of $9.27, for a total value of $278,100.00. Following the sale, the chairman now owns 651,291 shares in the company, valued at approximately $6,037,467.57. This trade represents a 4.40 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in Poseida Therapeutics during the second quarter worth approximately $31,000. Bayesian Capital Management LP acquired a new stake in Poseida Therapeutics in the first quarter valued at approximately $33,000. Rothschild Investment LLC acquired a new stake in Poseida Therapeutics in the second quarter valued at approximately $35,000. Principal Financial Group Inc. acquired a new stake in Poseida Therapeutics in the second quarter valued at approximately $35,000. Finally, Virtu Financial LLC bought a new stake in shares of Poseida Therapeutics during the 3rd quarter worth $37,000. 46.87% of the stock is currently owned by institutional investors.

About Poseida Therapeutics

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.